Harmony Biosciences Holdings, Inc.

Annual Trend FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Revenues
Gross profit $4.4m $132.0m $249.9m $354.4m $460.8m $557.9m $670.1m
Research and development $69.6m $19.4m $30.4m $70.9m $76.1m $145.8m $189.6m
Total operating expenses $150.3m $115.0m $162.4m $234.2m $268.8m $367.1m $461.6m
Operating income ($145.9m) $17.0m $87.5m $120.2m $192.0m $190.8m $208.5m
Net product revenue $6.0m $159.7m $305.4m $437.9m $582.0m $714.7m $868.5m
Sales and marketing $44.3m $55.8m $68.1m $79.3m $97.4m $110.9m $119.5m
General and administrative $36.4m $39.7m $63.9m $84.0m $95.3m $110.4m $152.5m
Loss on debt extinguishment $0 $8.6m $5.5m ($22.6m) ($26.1m) ($9.8m)
Interest income $224k $3.1m $14.7m $18.5m $21.9m
Unrealized income on investments ($151k) $153k $64k $280k
Comprehensive income ($318.5m) ($212.8m) ($108.0m) ($36.9m) $34.6m $181.3m $129.0m $145.6m $159.0m
Net premiums earned $2.3b $2.2b $2.3b $2.5b $2.4b $2.7b $2.6b $2.9b $2.8b
Net Investment Income $189.0m $198.2m $197.3m $154.6m $147.5m $188.1m $275.7m $318.0m $326.3m
Gain (loss) on investments $148.9m $110.0m $97.1m $98.5m $56.2m $5.0m $75.9m $52.6m $61.4m
Change in fair value of derivatives ($27.7m) $31.8m $144.2m $65.1m $35.9m $80.5m $26.1m ($21.1m) $47.5m
Realized and unrealized investment losses (3) $28.4m $174.7m $10.9m $27.4m $47.4m $182.6m ($61.4m) ($102.1m) ($72.3m)
Net realized and unrealized foreign exchange losses $23.9m $3.5m ($9.6m) ($13.8m) $40.0m $15.9m ($36.2m) $60.2m ($78.5m)
Change in net unrealized gains/(losses) on available for sale securities held ($10.8m) ($86.5m) $171.7m $175.6m ($137.2m) ($447.2m) $86.0m ($25.3m) $128.0m
Net change from current period hedged transactions $3.0m ($2.1m) $4.8m $300k ($6.2m) $15.4m ($14.0m) ($6.5m) $6.7m
Change in foreign currency translation adjustment ($56.4m) $21.5m ($28.2m) ($11.9m) $21.4m ($30.9m) $14.4m ($14.1m) $51.6m
Other comprehensive income, before income taxes ($68.2m) ($61.9m) $141.5m $96.9m ($142.4m) ($407.2m) $126.6m $13.5m $229.3m
Change in net unrealized (gains)/losses on available for sale securities held $1.6m $5.5m ($13.6m) ($500k) ($300k) $23.9m ($14.0m) $6.8m ($25.4m)
Other comprehensive income, net of tax ($50.8m) ($66.0m) $130.3m $96.4m ($142.7m) ($383.3m) $106.0m $10.2m $191.8m
Preference share dividends $44.5m $44.6m ($49.9m) ($54.9m) ($45.5m)
Other income $8.9m $9.0m $4.9m $49.8m $14.7m $8.2m $0 $0
Income (loss) from operations before income taxes ($281.8m) ($156.0m) ($216.6m) ($38.0m) $35.1m ($27.0m) $402.6m $464.1m
Reclassification adjustment for net realized losses on investments included in net /(loss) $0 $0 $6.6m
Related party fees ($10.3m) ($10.8m)
Interest on long-term debt $29.5m $25.9m $20.2m $33.9m $14.3m
Change in fair value of loan notes issued by variable interest entities ($21.2m) $4.4m $3.1m $0 $0
Amount attributable to non-controlling interest ($1.3m) ($1.0m) $1.2m $0 $0
Change in net unrealized gains on available for sale securities held ($800k) $0 $0
Other Comprehensive Income (Loss), Foreign Currency Translation Gain (Loss) Arising During Period, Tax $15.8m ($9.2m) ($3.2m) $0 $0
Equity method investment, realized gain (loss) on disposal $10.4m
Income before income taxes ($152.0m) ($36.9m) $37.4m $104.7m $173.4m $191.8m $215.1m
Net income ($267.7m) ($146.8m) ($152.0m) ($36.9m) $34.6m $181.5m $128.9m $145.5m $158.7m
Reclassification adjustment for net realized losses on investments included in net income $400k ($700k) $6.8m ($67.1m) ($20.4m) $55.5m $40.2m $59.4m $43.0m
Net income (loss) available to ordinary shareholders, basic ($14.7m) $6.5m $484.8m $431.2m $290.3m
Net income/(loss) ($266.4m) ($145.8m) ($239.5m) ($56.4m) $29.8m $51.1m $128.9m $145.5m $158.7m
Reclassification adjustment for net realized (losses)/gains on investments included in net income ($4.0m) $5.2m ($6.8m) ($67.1m)
Basic ($24.07) ($2.48) $0.60 $3.07 $2.17 $2.56 $2.76
Diluted ($24.07) ($2.48) $0.58 $2.97 $2.13 $2.51 $2.71
Weighted average number of shares of common stock - basic 7.8m 25.8m 57.5m 59.2m 59.5m 56.9m 57.5m
Weighted average number of shares of common stock - diluted 7.8m 25.8m 59.2m 61.1m 60.4m 57.9m 58.5m
Cost of product sold $1.6m $27.7m $55.5m $83.5m $121.2m $156.8m $198.3m
Other (expense) income, net ($3.1m) $16k $169k $159k ($68k) ($680k)
Interest expense $33.9m ($24.2m) ($18.8m) ($23.8m) ($17.5m) ($14.6m)
Income tax expense $15.4m $10.2m ($22.9m) ($18.4m) ($2.8m) $76.8m ($44.5m) ($46.3m) ($56.4m)
Losses and loss adjustment expenses $2.0b $1.6b $1.7b $1.8b $1.7b $1.7b ($1.6b) ($1.7b) ($1.5b)
Acquisition costs $400.5m $371.6m $412.7m $465.7m $414.1m $431.8m ($380.2m) ($420.2m) ($422.4m)
General, administrative and corporate expenses $502.2m $491.7m $521.6m $410.9m $418.0m $494.2m ($503.6m) ($533.1m) ($671.4m)
Other expenses $4.9m $2.7m $1.7m $10.8m $10.8m $20.1m $0 $0
Total expenses $2.9b $2.7b $2.8b $2.9b $2.6b $2.9b ($2.6b) ($2.8b) ($2.8b)
Total income tax (expense) allocated to other comprehensive income $17.4m ($4.1m) ($11.2m) ($500k) ($300k) $23.9m ($20.6m) ($3.3m) ($37.5m)

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.